Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.15 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)68.36K
Market Cap
€24.45M
Enterprise Value€28.61
Total Cash (Recent Filing)€1.01M
Total Debt (Recent Filing)€5.46M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Mar 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume46,175
30 Day Avg. Volume68,356
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundThe sustained revenue rebound across three reported years indicates improving commercial traction for Implanet’s orthopedic and spine products. Continued top-line expansion can broaden the company’s operating base, support greater utilization of its platform, and create a foundation for future operating leverage if costs are controlled.
Improving Gross MarginThe substantial gross-margin improvement suggests that the company is retaining more value from each product sale, which can strengthen the economics of its implant and instrumentation portfolio. If maintained, this improvement could provide greater capacity to fund commercial activity and help offset fixed operating costs over time.
Improving Operating Cash FlowAlthough operating cash flow remains negative, the sharp year-over-year improvement shows progress in converting the business into a more sustainable cash generator. Continued improvement would reduce funding pressure, increase financial flexibility, and potentially allow revenue growth and margin gains to translate into internally supported expansion.
Bears Say
Persistent Loss-Making OperationsPersistent operating and net losses show that revenue growth and stronger gross margin have not yet translated into a sustainable earnings model. Ongoing losses can consume financial resources, limit reinvestment capacity, and make the company more dependent on successful execution before its commercial progress produces durable shareholder value.
Highly Leveraged, Thin-Equity Balance SheetThe very small equity buffer relative to debt leaves Implanet vulnerable to continued losses and limits its ability to absorb setbacks. High leverage can constrain capital allocation, increase dependence on financing, and reduce strategic flexibility while the company works toward profitability and stronger internally generated funds.
Negative Free Cash Flow And Funding DependencePersistently negative free cash flow means the company is not yet funding its operations and investment needs from internally generated cash. Even with recent improvement, continued cash deficits can require external capital, potentially limiting growth choices and increasing financial pressure while profitability remains unresolved.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.15 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €24.45M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Mar 09, 2027 which is in 168 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Sep 15, 2026. The company reported -€0.015 earnings per share for the quarter.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -0.581%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Affluent Medical SA
―